search

Active clinical trials for "Lymphoma, Large-Cell, Anaplastic"

Results 51-60 of 200

Ceritinib Rare Indications Study in ALK+ Tumors

Tumors With Aberrations in ALKAnaplastic Large Cell Lymphoma2 more

This is Proof-of-Concept (POC) study to assess the preliminary antitumor activity and safety and tolerablity using ceritinib (LDK378) in the treatment of life threatening tumors that are characterized by ALK genetic alteration (and/or overexpression in some diseases).

Terminated18 enrollment criteria

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

ALK+ Anaplastic Large Cell Lymphoma

This is an open label pilot study of combining BV in a licensed indication with imatinib in patients with ALCL. It is intended as a "window of opportunity" trial in which the study drugs will be given as an initial substitute for conventional chemotherapy with the intention to achieve a remission enabling the patients to proceed to autologous or allogeneic stem cell transplantation, if eligible.

Terminated33 enrollment criteria

Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With...

Anaplastic Large Cell LymphomaBurkitt Lymphoma3 more

This clinical trial studies blood sample markers of reproductive hormones in assessing ovarian reserve in younger patients with newly diagnosed lymphomas. Studying samples of blood from patients with cancer in the laboratory may help measure the effect of curative therapy for lymphoma on ovarian failure.

Active15 enrollment criteria

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Blastic Plasmacytoid Dendritic Cell NeoplasmHepatosplenic T-Cell Lymphoma18 more

This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells.

Terminated52 enrollment criteria

PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable...

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell Lymphoma59 more

This phase I trial is studying the side effects and best dose of giving PDX101 together with 17-AAG in treating patients with metastatic or unresectable solid tumors or lymphoma. PDX101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving PXD101 together with 17-AAG may kill more cancer cells.

Terminated31 enrollment criteria

Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

Peripheral T-cell LymphomasAdult T-cell Leukemia6 more

The purpose of this study is to: assess the effectiveness of lenalidomide for the treatment of patients with relapsed and or refractory peripheral T-cell lymphomas; and, assess the safety of lenalidomide. There are reports suggesting a therapeutic benefit of thalidomide in patients with refractory and/or relapsed Non-Hodgkin's Lymphoma's (NHL) which have led to the formal investigation of lenalidomide in the treatment of relapsed NHL's.

Terminated32 enrollment criteria

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin Lymphoma26 more

This phase I/II trial is studying the side effects and best dose of flavopiridol and to see how well it works in treating patients with lymphoma or multiple myeloma. Drugs used in chemotherapy, such as flavopiridol, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Terminated78 enrollment criteria

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced...

NeoplasmsColorectal Neoplasms30 more

This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.

Terminated29 enrollment criteria

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing...

Hodgkin LymphomaPeripheral T Cell Lymphoma1 more

This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stopping treatment.

Terminated16 enrollment criteria

Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin...

Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell Lymphoma32 more

This pilot phase I/II trial studies the side effects and best of dose ipilimumab when given together with local radiation therapy and to see how well it works in treating patients with recurrent melanoma, non-Hodgkin lymphoma, colon, or rectal cancer. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Radiation therapy uses high energy x rays to kill cancer cells. Giving monoclonal antibody therapy together with radiation therapy may be an effective treatment for melanoma, non-Hodgkin lymphoma, colon, or rectal cancer

Terminated42 enrollment criteria
1...567...20

Need Help? Contact our team!


We'll reach out to this number within 24 hrs